

LA JOLLA PHARMACEUTICAL CO  
Form 8-K  
January 30, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): January 30, 2018

---

LA JOLLA PHARMACEUTICAL COMPANY  
(Exact name of registrant as specified in its charter)

---

California 1-36282 33-0361285  
(State or other jurisdiction of incorporation or organization) (Commission (I.R.S. Employer  
File Number) Identification No.)

4550 Towne Centre Court, San Diego, California 92121  
(Address of Principal Executive Offices) (Zip Code)  
Registrant's telephone number, including area code: (858) 207-4264

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously  
satisfy the filing obligation of the registrant under any of the following provisions  
(see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act  
(17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  
(17 CFR 240.13e-4(c))

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition  
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the  
Exchange Act.

ITEM 8.01 OTHER EVENTS.

On January 30, 2018, La Jolla Pharmaceutical Company established a wholesale acquisition cost of \$1,500 per vial for a 1 mL, single-dose, 2.5 mg/mL vial of GIAPREZA™ (angiotensin II).

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

Date: January 30, 2018 /s/ Dennis M. Mulroy  
Dennis M. Mulroy  
Chief Financial Officer